Sotabase

Career

· Business & Mindset Coach for Women, Emily Collins' business and coaching platform2025–
· Business & Mindset Coach for Women, emilycollins.com2025–
· Researcher (implied from context), CIMAS at University of Miami2016–
· Phoenix Contact Worldwide

Publications (43)

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Journal of the American Medical Association (JAMA) · 2023
1,675
cited
Application of neurite orientation dispersion and density imaging (NODDI) to a tau pathology model of Alzheimer's disease
NeuroImage · 2016
208
cited
Development of a novel antibody to calcitonin gene-related peptide for the treatment of osteoarthritis-related pain.
Osteoarthritis and Cartilage · 2014
111
cited
In vivo imaging of tau pathology using multi-parametric quantitative MRI
NeuroImage · 2015
87
cited
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers
Frontiers in Pharmacology · 2017
63
cited
Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease
NeuroImage · 2017
60
cited
Translational Pharmacodynamics of Calcitonin Gene-Related Peptide Monoclonal Antibody LY2951742 in a Capsaicin-Induced Dermal Blood Flow Model
Journal of Pharmacology and Experimental Therapeutics · 2015
58
cited
Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy
Front. Neuroinform. · 2017
49
cited
Imaging the accumulation and suppression of tau pathology using multiparametric MRI
Neurobiology of Aging · 2016
43
cited
Increased Cerebral Vascular Reactivity in the Tau Expressing rTg4510 Mouse: Evidence against the Role of Tau Pathology to Impair Vascular Health in Alzheimer's Disease
Journal of Cerebral Blood Flow and Metabolism · 2015
27
cited
Study the Longitudinal in vivo and Cross-Sectional ex vivo Brain Volume Difference for Disease Progression and Treatment Effect on Mouse Model of Tauopathy Using Automated MRI Structural Parcellation
Frontiers in Neuroscience · 2019
26
cited
Verifiable Self-Certifying Autonomous Systems
2018 IEEE International Symposium on Software Reliability Engineering Workshops (ISSREW) · 2018
25
cited
PET quantification of brain O-GlcNAcase with [18F]LSN3316612 in healthy human volunteers
EJNMMI Research · 2020
19
cited
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme: Translation from rat to human
Alzheimer's & Dementia · 2020
18
cited
Tau as a diagnostic instrument in clinical trials to predict amyloid in Alzheimer's disease
Alzheimer's & Dementia · 2023
14
cited
TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment
Alzheimer's & Dementia · 2021
13
cited
In Vivo Imaging of Tau Pathology Using Magnetic Resonance Imaging Textural Analysis
Frontiers in Neuroscience · 2017
12
cited
TRPA1 Antagonist LY3526318 Inhibits the Cinnamaldehyde‐Evoked Dermal Blood Flow Increase: Translational Proof of Pharmacology
Clinical pharmacology and therapy · 2023
12
cited
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
Alzheimer's & Dementia · 2021
8
cited
Perspectives on Cognitive Phenotypes and Models of Vascular Disease.
Arteriosclerosis, Thrombosis and Vascular Biology · 2022
6
cited
Sotabase
Emily Collins | Researcher Profile | Sotabase | Sotabase